Back to Search
Start Over
FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
- Source :
- npj Breast Cancer, Vol 7, Iss 1, Pp 1-9 (2021), NPJ breast cancer, 7 (1, NPJ Breast Cancer, NPJ breast cancer, Vol. 7, no.1, p. 125 (2021)
- Publication Year :
- 2021
- Publisher :
- NATURE PORTFOLIO, 2021.
-
Abstract
- Biomarkers to identify patients without benefit from adding everolimus to endocrine treatment in metastatic breast cancer (MBC) are needed. We report the results of the Pearl trial conducted in five Belgian centers assessing 18F-FDG-PET/CT non-response (n = 45) and ctDNA detection (n = 46) after 14 days of exemestane-everolimus (EXE-EVE) to identify MBC patients who will not benefit. The metabolic non-response rate was 66.6%. Median PFS in non-responding patients (using as cut-off 25% for SUVmax decrease) was 3.1 months compared to 6.0 months in those showing response (HR: 0.77, 95% CI: 0.40–1.50, p = 0.44). The difference was significant when using a “post-hoc” cut-off of 15% (PFS 2.2 months vs 6.4 months). ctDNA detection at D14 was associated with PFS: 2.1 months vs 5.0 months (HR-2.5, 95% CI: 1.3–5.0, p = 0.012). Detection of ctDNA and/or the absence of 18F-FDG-PET/CT response after 14 days of EXE-EVE identifies patients with a low probability of benefiting from treatment. Independent validation is needed.<br />SCOPUS: ar.j<br />info:eu-repo/semantics/published
- Subjects :
- Oncology
medicine.medical_specialty
TRASTUZUMAB
FDG-Positron Emission Tomography
Article
Breast cancer
Internal medicine
medicine
Endocrine system
Pharmacology (medical)
Radiology, Nuclear Medicine and imaging
COMBINATION
RC254-282
Everolimus
Science & Technology
LANDSCAPE
business.industry
MUTATIONS
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Généralités
medicine.disease
Metastatic breast cancer
CELL-FREE DNA
Biomarker (medicine)
business
Life Sciences & Biomedicine
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- npj Breast Cancer, Vol 7, Iss 1, Pp 1-9 (2021), NPJ breast cancer, 7 (1, NPJ Breast Cancer, NPJ breast cancer, Vol. 7, no.1, p. 125 (2021)
- Accession number :
- edsair.doi.dedup.....72d8f069d47521537470c721c93fd931